ADMP -40% on phase-2/3 COVID failure: https://www.globenewswire.com/news-release/2022/09/21/2520081/32832/en/Adamis-Provides-Update-on-the-Phase-2-3-Trial-of-Tempol-in-COVID-19-Positive-High-Risk-Subjects.html